
GMAB Stock Forecast & Price Target
GMAB Analyst Ratings
Bulls say
Genmab reported operating income that exceeded expectations by 20%, highlighting the company's efficient management and robust financial performance amidst a challenging biotech sector. The ongoing success of Darzalex, along with its promising pipeline of candidates set to yield pivotal read-outs by 2026, positions Genmab well for future revenue growth and diversification. With approximately $3.4 billion in cash and marketable securities, Genmab's strong balance sheet supports its capability to navigate potential market fluctuations while capitalizing on significant future opportunities.
Bears say
The analysis of Genmab's financial outlook reveals a series of substantial risks contributing to a negative sentiment regarding the stock's future performance. Key concerns include slowing sales of Genmab's flagship product, Darzalex, potential failures in obtaining label extensions, unanticipated negative readouts from ongoing trials, and a lack of market penetration for emerging products like Epcoritamab. Additionally, the decision to discontinue development of the program GEN1042 and uncertainties surrounding clinical or regulatory outcomes for critical pipeline products intensify the outlook, raising questions about the company's long-term growth prospects and market competitiveness.
This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.
GMAB Analyst Forecast & Price Prediction
Start investing in GMAB
Order type
Buy in
Order amount
Est. shares
0 shares